Finance

Lists
002773:SHE
Chengdu Kanghong Pharma Grp Co Ltd
19,44 CN¥
-1,92%
(-0,38) 1D
16 հոկ, 15:04:09 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002773...
Open
20,34 CN¥
High
20,34 CN¥
Low
19,30 CN¥
Mkt. cap
18,26 մլրդ
Avg. vol.
7,30 մլն
Volume
6,59 մլն
Dividend
3,60%
Quarterly dividend
0,17 CN¥
Ex-dividend date
09 հնս, 2026 թ.
P/E ratio
18,00
52-wk high
36,10 CN¥
52-wk low
18,62 CN¥
EPS
1,08 CN¥
Shares outstanding
921,33 մլն
No. of employees
4 հզր
Open
20,34 CN¥
High
20,34 CN¥
Low
19,30 CN¥
Mkt. cap
18,26 մլրդ
Avg. vol.
7,30 մլն
Volume
6,59 մլն
Dividend
3,60%
Quarterly dividend
0,17 CN¥
Ex-dividend date
09 հնս, 2026 թ.
P/E ratio
18,00
52-wk high
36,10 CN¥
52-wk low
18,62 CN¥
EPS
1,08 CN¥
Shares outstanding
921,33 մլն
No. of employees
4 հզր
News stories
From web sources and news partners
Profile
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, central nervous, digestive and endocrine systems. The company is listed on the Shenzhen stock exchange with a market capitalization at around $6 billion. As of May 2021, the company had 18 drugs on the market including Lumitin. Additional products include Songling xuemaikang capsules, Keluoxin capsules, Xinluona, Bolexin and Bosiqing, Yitaning, Shugan Jieyu, Danshu, and Yiqing. Kanghong also currently has 13 subsidiaries in China, Israel, and the United States. Wikipedia
About Chengdu Kanghong Pharma Grp Co Ltd
CEO-
Employees4,47 հզր
Founded03 հոկ, 1996 թ.
Headquarters-
Sector-
Websitecnkh.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
1,17 մլրդ
961,27 մլն
1,05 մլրդ
1,13 մլրդ
Cost of goods sold
103,16 մլն
116,91 մլն
118,65 մլն
132,03 մլն
Cost of revenue
103,16 մլն
116,91 մլն
118,65 մլն
132,03 մլն
Research and development expenses
119,54 մլն
198,94 մլն
86,77 մլն
138,57 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
595,28 մլն
521,75 մլն
478,88 մլն
554,55 մլն
Operating expense
697,02 մլն
764,40 մլն
582,81 մլն
717,78 մլն
Total operating expenses
800,18 մլն
881,31 մլն
701,46 մլն
849,80 մլն
Operating income
370,02 մլն
79,96 մլն
345,02 մլն
282,88 մլն
Other non operating income
-19,53 մլն
19,27 մլն
-1,04 մլն
-1,54 մլն
EBT including unusual items
355,99 մլն
147,66 մլն
358,51 մլն
301,88 մլն
EBT excluding unusual items
364,66 մլն
135,96 մլն
356,39 մլն
306,28 մլն
Income tax expense
56,73 մլն
23,28 մլն
55,31 մլն
50,13 մլն
Effective tax rate
15,94%
15,77%
15,43%
16,61%
Other operating expenses
-17,83 մլն
43,89 մլն
16,62 մլն
23,18 մլն
Net income
303,21 մլն
130,06 մլն
307,48 մլն
257,26 մլն
Net profit margin
25,91%
13,53%
29,38%
22,71%
Earnings per share
-
-
-
-
Interest and investment income
14,20 մլն
36,91 մլն
12,63 մլն
24,92 մլն
Interest expense
-
-
-
-
Net interest expenses
14,20 մլն
36,91 մլն
12,63 մլն
24,92 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
427,31 մլն
139,05 մլն
404,11 մլն
345,15 մլն
Gain or loss from assets sale
3,47 հզր
-9,78 հզր
-
61,06 հզր
AI content may include mistakes. Learn more
Google Apps